Cargando…
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
BACKGROUND: Idiopathic Pulmonary Fibrosis is a chronic, progressive interstitial lung disease for which there is no cure. However, lung function decline, hospitalizations, and mortality may be reduced with the use of the antifibrotic medications, nintedanib and pirfenidone. Historical outcomes for h...
Autores principales: | Kelly, Bryan T., Thao, Viengneesee, Dempsey, Timothy M., Sangaralingham, Lindsey R., Payne, Stephanie R., Teague, Taylor T., Moua, Teng, Shah, Nilay D., Limper, Andrew H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286036/ https://www.ncbi.nlm.nih.gov/pubmed/34273943 http://dx.doi.org/10.1186/s12890-021-01607-2 |
Ejemplares similares
-
Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment
por: Herberts, Michelle B., et al.
Publicado: (2023) -
Reply: Adoption of Antifibrotic Medications: A Closer Look at the Data
por: Dempsey, Timothy M., et al.
Publicado: (2021) -
Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis
por: Teague, Taylor T., et al.
Publicado: (2022) -
Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022) -
ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017)